scholarly journals The Use of Real-World Data to Evaluate the Association Between Atopic Dermatitis and Cardiovascular Disease: A Retrospective Claims Analysis

2021 ◽  
Vol 11 (5) ◽  
pp. 1707-1715
Author(s):  
Jashin J. Wu ◽  
Caroline Amand ◽  
Daniel J. No ◽  
Puneet Mahajan ◽  
Abhijit Gadkari ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Atopic Dermatitis ◽  
Real World ◽  
Claims Analysis ◽  
Real World Data ◽  
World Data

27434 Early trends of disease improvement in adult patients with atopic dermatitis treated with dupilumab: Real-world data from the PROSE registry

2021 ◽  
Vol 85 (3) ◽  
pp. AB32
Author(s):  
Jerry Bagel ◽  
Gil Yosipovitch ◽  
David M. Pariser ◽  
Robert Y. Lin ◽  
Haixin Zhang ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Real World ◽  
Adult Patients ◽  
Real World Data ◽  
World Data

13605 Burden of atopic dermatitis: Real-world data from a large nationwide health care provider

2020 ◽  
Vol 83 (6) ◽  
pp. AB9
Author(s):  
Clara Weil ◽  
Philip Sugerman ◽  
Gabriel Chodick ◽  
Huifang Liang ◽  
Hongwei Wang ◽  
...  
Keyword(s):  
Health Care ◽  
Atopic Dermatitis ◽  
Health Care Provider ◽  
Real World ◽  
Care Provider ◽  
Real World Data ◽  
World Data

scholarly journals Cost-Effectiveness of SGLT2is Versus DPP4is Among Type 2 Diabetes Patients with and Without Established Cardiovascular Disease: A Model-Based Simulation Analysis Using 10-Year Real-World Data and Systematic Review

2021 ◽  
Author(s):  
Zi-Yang Peng ◽  
Chun-Ting Yang ◽  
Huang-Tz Ou ◽  
Shihchen Kuo
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Cost Effectiveness ◽  
Cost Saving ◽  
Real World ◽  
Cost Effective ◽  
Real World Data ◽  
World Data

Abstract Background: We conducted a model-based economic analysis of sodium-glucose cotransporter-2 inhibitors (SGLT2is) versus dipeptidyl peptidase-4 inhibitors (DPP4is) in type 2 diabetes (T2D) patients with and without established cardiovascular disease (CVD) using 10-year real-world data. Methods: A Markov model was utilized to estimate healthcare costs and quality-adjusted life-years (QALYs) over a 10-year simulation time horizon from a healthcare sector perspective, with both costs and QALYs discounted at 3% annually. Model inputs were derived from analyses of Taiwan’s National Health Insurance Research Database or published studies of Taiwanese populations. The primary outcome measure was the incremental cost-effectiveness ratios (ICERs). Incorporated with our study findings, a structured systematic review was conducted to synthesize updated evidence on the cost-effectiveness of SGLT2is versus DPP4is. Results: Over 10 years, use of SGLT2is versus DPP4is yielded ICERs of $3,244 and $4,186 per QALY gained for T2D patients with and without established CVD, respectively. Results were robust across a series of sensitivity and scenario analyses, showing ICERs between $-1,074 (cost-saving) and $8,467 per QALY gained for T2D patients with established CVD and between $369 and $37,122 per QALY gained for T2D patients without established CVD. A systematic review revealed a cost-effective or even cost-saving profile of using SGLT2is for T2D treatment. Conclusions: Use of SGLT2is versus DPP4is was highly cost-effective for T2D patients regardless of patients’ CVD history in real-world clinical practice. Our results extend current evidence by demonstrating SGLT2is as an economically rational alternative over DPP4is for T2D treatment in routine care. Future research is warranted to explore heterogenous economic benefits of SGLT2is given diverse patient characteristics in clinical settings.

Abstract #946: Assessment of Acromegaly Patients with and Without Diabetes Treated with Lanreotide Depot: 2-Year Real World Data

2016 ◽  
Vol 22 ◽  
pp. 219
Author(s):  
Roberto Salvatori ◽  
Olga Gambetti ◽  
Whitney Woodmansee ◽  
David Cox ◽  
Beloo Mirakhur ◽  
...  
Keyword(s):  
Real World ◽  
Real World Data ◽  
World Data
Sign in / Sign up

Export Citation Format

Share Document